Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publicado em
- 30 abr 2026
- Citações
- 7
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
Deborah Konopnicki, Christine Gilles, Yannick Manigart, Patricia Barlow, Anca Reschner, Coca Necsoi, Marc Delforge, Davy Vanden Broeck, Nicolas Dauby, Stéphane De Wit
Descritores MeSH
- Immunogenicity, Vaccine
- HIV Infections
- Papillomavirus Infections
- Papillomavirus Vaccines
- Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
- Adult
- Antibodies, Viral
- Female
- Humans
- Immunization Schedule